Bank of America analysts have expressed concerns about Novo Nordisk potentially missing first-quarter expectations due to slower sales of its Wegovy and Ozempic drugs. This might lead the Danish pharmaceutical company to revise downwards its 2025 guidance during the quarterly results announcement. BofA's global research suggests a possible 2% decrease in Novo Nordisk's annual sales guidance, projecting a revised sales growth range of 14% to 22% for the year. The analysts highlighted factors such as sluggish trends in Ozempic and Wegovy sales, adverse currency effects, and potential increases in selling and administrative expenses necessary for demand generation and rebuilding physician confidence in the company's supply. Novo Nordisk's leading position in the weight-loss drug market was challenged by the launch of Eli Lilly's Zepbound, reigniting concerns among investors and causing a decline in Novo Nordisk's shares. Despite maintaining a positive outlook on the stock, Bank of America slightly adjusted its price target for Novo Nordisk. Analysts will be closely monitoring Novo's upcoming quarterly earnings report scheduled for May 7.